• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percent of Office of In Vitro Diagnostics and Radiological Health (OIR) intra- and inter-Office eConsults completed on time during the month

Dictionary: CDRH uses the internal expert consultation process to acquire information and analysis on issues related to medical devices. Intra- and inter-office consultations are completed for a variety of work products requiring expertise within and across CDRH offices, including premarket device submissions, post-approval studies, and compliance and enforcement actions. Inter-office eConsults are used to facilitate the exchange of scientific information and staff expertise across CDRH, critical to making well-supported regulatory decisions. eConsult is the system CDRH uses to manage and monitor expert consult requests.

Information is current as of September 30, 2013

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetPercent
Oct 20118594
Nov 20118592
Dec 20118594
Jan 20128597
Feb 20128595
Mar 20128597
Apr 20128597
May 20128597
Jun 20128594
Jul 20128593
Aug 20128599
Sep 20128595

FY 2012 Overall: 95%

Number of OIR intra- and inter-Office eConsults completed on time during the month

Fiscal Year - 2012
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2011N/A193
Nov 2011N/A181
Dec 2011N/A272
Jan 2012N/A247
Feb 2012N/A305
Mar 2012N/A309
Apr 2012N/A261
May 2012N/A265
Jun 2012N/A242
Jul 2012N/A229
Aug 2012N/A330
Sep 2012N/A208

FY 2012 Total: 3,042

Total number of OIR intra- and inter-Office eConsults completed during the month

Fiscal Year - 2012
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2011N/A205
Nov 2011N/A197
Dec 2011N/A290
Jan 2012N/A255
Feb 2012N/A321
Mar 2012N/A319
Apr 2012N/A270
May 2012N/A273
Jun 2012N/A257
Jul 2012N/A246
Aug 2012N/A334
Sep 2012N/A220

FY 2012 Total: 3,187

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.